During January, CareDx closed a public offering that raised approximately $164 million in net proceeds. The company also announced ranges of record-high revenue for the fourth quarter and all of 2020, with full Q4 and full-year results to be released in February . . .

Get GEN Edge Today!

The post CareDx Adds Infectious Disease Focus to Transplant Diagnostics with IDbyDNA appeared first on GEN – Genetic Engineering and Biotechnology News.